标题: Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic [打印本页] 作者: StephenW 时间: 2011-12-11 11:01 标题: Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic
Summary. There are few reports on hepatitis B e antigen (HBeAg) titres
during nucleos(t)ide analogues treatment. We investigated the changes in
HBeAg levels in patients treated with entecavir and the usefulness of HBeAg
quantification for predicting antiviral response. Ninety-five consecutive
HBeAg-positive patients treated with entecavir for more than 48 weeks were
enrolled. Serum levels of hepatitis B surface antigen (HBsAg), HBeAg and
HBV DNA were assessed at 4-week intervals to week 24 and thereafter at
12-week intervals. Virologic response (Y1VR) was defined as an undetectable
HBV DNA level at week 48 of therapy. During 48 weeks, HBeAg and HBV DNA
level decreased significantly in a biphasic manner and HBsAg level tended
to decease. Fifty-three patients (55.8%) attained Y1VR. Pretreatment HBeAg
levels were significantly lower in the Y1VR group than in no Y1VR group. At
week 4 and 12 of therapy, 25% and 41.4% of patients showed a decrease of
HBeAg levels with >0.5 log10 and >1.0 log10 from baseline, respectively.
These patients achieved more Y1VR than those with less decrease of HBeAg
levels (97.7%vs 22.2% and 86.2%vs 29.3%, respectively). HBeAg level at week
12 had higher predictive values for Y1VR than HBV DNA level. Multivariate
analysis revealed that a pretreatment HBeAg level of <360 PEIU/mL and the
reduction in HBeAg level >1.0 log10 at week 12 were associated with Y1VR.
These results suggest that pretreatment HBeAg level and an early decrease
in HBeAg level are useful measurements for predicting one-year virologic
response during entecavir treatment.